Back to the main directory
EarningsReview / Equity
- CMD preview: green rush, but where''s the gold? by BNP Paribas Exane
- Leafing through the data - the Fall edition by BNP Paribas Exane
- Conference Guide 2023 by BNP Paribas Exane
- INVEST SECURITIES – INTRASENSE : S1 conforme mais encore trop peu savoureux - NEUTRE, OC 0,48€ vs 0,53€ by Invest Securities
- Robertet - Un S1 conforme aux attentes by MidCap Partners
- Solutions 30 - Mixed H1 Margin Levels by MidCap Partners
- Robertet - H1 In Line With Expectations by MidCap Partners
- Immix Biopharma - NXC-201 gains orphan drug designation in ALA by Edison Investment Research
- Are Renewables in Crisis? by BNP Paribas Exane
- Wanda Film (002739 CH) by HSBC
- 万达电影（002739 CH） by HSBC
- 光线传媒（300251 CH） by HSBC
- What to expect from the Solaria CMD? by BNP Paribas Exane
- U-turn in DAXXIFY pricing strategy vs. BOTOX by BNP Paribas Exane
- Weekly prescription tracker by BNP Paribas Exane
- HgCapital Trust - Seizing ‘buy-and-build’ opportunities by Edison Investment Research
- Namibian EandP - what do we know, where might it go? by BNP Paribas Exane
- Vietnam: looking beyond the short-term by BNP Paribas Exane
- The return of the Jedi by BNP Paribas Exane
- Macro, Valuation, Exposures, Sensitivities and Performance Sheets by BNP Paribas Exane
- Postcard from San Jose. GenAI adoption before monetisation by BNP Paribas Exane
- Sustainability Weekly 18 – 22 September 2023 by Oddo BHF
- INVEST SECURITIES – ALTEN : Tentant, mais encore un peu tôt - NEUTRE, OC 136€ vs 142€ by Invest Securities
- Maps - Une S1 d’intégration et positionnement de la BU Energy by MidCap Partners
- Ilpra - H1 2023: Double-Digit Growth by MidCap Partners